Clinical Trial

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Study acronym: PARAISO
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
Protocol Amendment History 5 changes
notable Trial sites expanded: 174 -> 184 locations 2026-08-07
notable Trial sites expanded: 160 -> 174 locations 2026-07-07
notable Trial sites expanded: 142 -> 160 locations 2026-06-05
notable Trial sites expanded: 101 -> 142 locations 2026-05-07
notable Trial sites expanded: 66 -> 101 locations 2026-04-07
Trial Details
NCT Number NCT07174310
Lead Sponsor Hoffmann-La Roche
Collaborators: Prothena Biosciences Limited
Conditions Parkinson's Disease
Enrollment 900 participants
Start Date 2025-11-24
Primary Completion 2029-06-30 (estimated)
Study Completion 2031-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-06